Retrophin, Inc. (RTRX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Retrophin, Inc. (NASDAQ:RTRX) have received a consensus recommendation of “Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $36.00.

Several equities analysts recently issued reports on RTRX shares. ValuEngine lowered shares of Retrophin from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 price target on shares of Retrophin in a report on Friday, October 6th. BidaskClub raised shares of Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Finally, Zacks Investment Research lowered shares of Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/retrophin-inc-rtrx-given-consensus-recommendation-of-buy-by-analysts.html.

Retrophin (NASDAQ RTRX) opened at $20.93 on Tuesday. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. Retrophin has a 1-year low of $15.55 and a 1-year high of $26.44.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). The business had revenue of $40.34 million for the quarter, compared to analysts’ expectations of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.09) earnings per share. equities research analysts expect that Retrophin will post -1.25 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Perceptive Advisors LLC lifted its stake in shares of Retrophin by 0.5% during the third quarter. Perceptive Advisors LLC now owns 2,686,204 shares of the biopharmaceutical company’s stock worth $66,859,000 after buying an additional 13,895 shares during the period. OxFORD Asset Management LLP lifted its position in Retrophin by 71.4% during the third quarter. OxFORD Asset Management LLP now owns 59,768 shares of the biopharmaceutical company’s stock valued at $1,497,000 after purchasing an additional 24,906 shares during the period. Dimensional Fund Advisors LP lifted its position in Retrophin by 8.7% during the third quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock valued at $22,322,000 after purchasing an additional 71,562 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Retrophin by 4.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 289,674 shares of the biopharmaceutical company’s stock valued at $7,210,000 after purchasing an additional 11,986 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Retrophin during the third quarter valued at $249,000.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply